

Indian Journal of Skin Allergy



Author's reply

Pembrolizumab-induced resolving papulosquamous eruption: An enigmatic presentation in a patient with renal cell carcinoma

Avik Mondal¹

¹Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.

I want to thank the authors for their interest in my article.^[1] In their "letter to the editor," they have mainly stressed on the cutaneous manifestations and paraneoplastic conditions that may be found in renal cell carcinoma patients. [2] They have not raised any obvious queries regarding my article, which clearly mentioned that the patient was diagnosed case of renal cell carcinoma and the papulosquamous eruption appeared after starting pembrolizumab and lenvatinib. Further, whenever, pembrolizumab was withdrawn, the lesions had a spontaneous resolution. Therefore, based on this finding, a cutaneous association with renal cell carcinoma itself is unlikely, and it was the drug that was causing the development of papulosquamous eruption. However, I completely agree with their conclusion that we must not forget "the great imitators," and in individual cases, care should be taken to delineate a drug eruption from a paraneoplastic condition to optimize the management.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

REFERENCES

- Mondal A. Pembrolizumab-induced resolving papulosquamous eruption: An enigmatic presentation in a patient with renal cell carcinoma. Indian J Skin Allergy 2024;3:119-21.
- Santos VM, Sugai TA, Santos LA. Renal cell carcinoma and cutaneous paraneoplastic syndromes. Indian J Skin Allergy 2024;3:149-50.

How to cite this article: Mondal A. Pembrolizumab-induced resolving papulosquamous eruption: An enigmatic presentation in a patient with renal cell carcinoma. Indian J Skin Allergy. 2024;3:151. doi: 10.25259/IJSA_41_2024

Received: 25 July 2024 Accepted: 25 July 2024 EPub Ahead of Print: 12 August 2024 Published: 17 October 2024 DOI: 10.25259/IJSA_41_2024

^{*}Corresponding author: Avik Mondal, Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.